Zdrowie i gospodarka · 27/06/1994
Opportunity For Licensing: Neutralizing Monoclonal Antibodies for Respiratory Syncytial Virus
The National Institutes of Health (NIH) is seeking a licensee to develop human monoclonal antibodies against respiratory syncytial virus (RSV) through preclinical, clinical, and commercial stages.